September 21st 2023
The expanded indication to those with severe hepatic impairment has already been granted in the US and EU.
September 13th 2023
Several trial participants experienced concerning hepatobiliary events.
August 10th 2023
The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.
August 1st 2023
The CDC made this recommendation after reviewing relevant literature, and noting that complete testing jumped from about only two-thirds of patients to nearly all patients.
July 31st 2023
The vaccine has been approved since late 2019 for adults age 18 and older.
WHO Updates Recommendations for HIV, Hepatitis, STI Interventions in Prisons
The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
Seattle Medical Center Investigates Deadly Klebsiella pneumoniae Outbreak
So far, the Virginia Mason Medical Center in Seattle has confirmed 33 patients have been infected with Klebsiella pneumoniae bacteria, 9 of whom have died.
A Candid Look Into Uncomplicated Candida Bloodstream Infection Treatment Durations
Can COVID-19 Vaccination Reduce Hepatitis B Viral Load?
Some chronic hepatitis B patients experienced a dramatic decrease in hepatitis B surface antigen (HBsAg) after receiving a COVID-19 vaccine. Could there be a correlation?
7 Stories for February 7: Observing National Black HIV/AIDS Awareness Day
February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.
Marburg Virus Investigational Vaccine Safe and Immunogenic in Humans
This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.
World Neglected Tropical Diseases Day, Explained
These diseases, exacerbated by poor water quality, sanitation, and health care access, are highlighted today.
Looking to Safeguard Blood Supply, FDA Proposes Risk Assessment for Blood Donations
The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.
This Week in Infectious Disease, Recapped
Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.
Hepatitis C Treatment Also Reduces Liver Disease and Death
What is the hepatitis C treatment uptake among people who inject drugs?
Deadly Ebola Outbreak Is Over, Uganda Declares
After their first Sudan ebolavirus outbreak in 10 years, resulting in 164 cases, Uganda today announced the Ebola outbreak is over.
Would You Try Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia?
This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.
Investigational HBV Treatment Moves Goal from Suppression to Cure
Phase 2 trial with bepirovirsen demonstrates possibility of a functional cure of chronic hepatitis B infection that is sustained after treatment is discontinued.
Type I Interferon Response Linked to Resistance to HCV Infection
Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.
Measuring Disease Severity, Quality of Life in Japanese Hepatitis Patients
As viral hepatitis is the most common blood-transmitted infection globally, assessing the toll of hepatitis and hepatitis-related conditions is critical.
Breakthrough Therapy Bulevirtide was Safe, Effective, and Improved Quality of Life for Hepatitis Patients
Three posters on the subject were presented at The Liver Meeting and were among the meeting’s key presentation highlights called “Best of the Liver Meeting.”
Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Automatic Letters Help Boost Screenings for Hepatitis C
About a third of veterans who received a letter to get tested for hepatitis C did so, according to a study by the Veterans Affairs Greater Los Angeles Healthcare System.
Hepatitis C Can Be Cured in Young People Who Inject Drugs
Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.
Positive Phase 1 Data Reported for Dengue Antiviral
Dengue is the most prevalent and important mosquito-borne virus in the world. Atea Pharmaceuticals presented positive data for their direct-acting dengue antiviral, AT-752.
Recent Research Indicates That We're Falling Short on HBV Elimination Targets
Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
With Ebola Outbreak, Uganda Places Two Regions in Lockdown
That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.
Among People with Hemophilia, HCV Prevention is Working, But Eradication Remains Elusive
A new review article suggests it is possible to eradicate hepatitis C virus infections among people with hemophilia, but it will take intense focus from public health agencies.
Hepatitis A Vaccination Efforts Can Reduce Spread
Hepatitis A infections occurred almost exclusively among adults in states with outbreaks.
Hepatitis C: Time to Treatment Varies by Insurance Type
“Too few persons are receiving timely treatment” with direct-acting antiviral for hepatitis C based on their first positive test result, the study authors wrote.
Bulevirtide Shows Promise for Treating Hepatitis
Bulevirtide, a first-in-class entry inhibitor, showed promise for the treatment of hepatitis B and hepatitis D coinfection, a phase 2 trial found.
To Eliminate Hepatitis by 2030, Hepatitis B Needs More Attention
Experts are advocating for occult hepatitis B to be spotlighted.
Uganda Declares Ebola Outbreak Caused by Sudan Virus
Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.
Occult Hepatitis B Virus Infection: Underestimated Global Health Threat
Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.
Non-Targeted Screening Program Could Identify More HCV Infections
With an all-ready challenging patient population to treat, having a program to get more people into treatment can be helpful in an underserved group.
2 Clarke Drive Cranbury, NJ 08512